RXi Pharmaceuticals
and TransDerm Announce Formation of Research Collaboration
April 06, 2010
WORCESTER, Mass. & SANTA CRUZ, Calif.--(BUSINESS
WIRE)--RXi Pharmaceuticals
Corporation (Nasdaq:
RXII), a
biopharmaceutical company pursuing the development and
commercialization of proprietary therapeutics based on
RNA interference
(RNAi), and TransDerm, Inc.,
a biopharmaceutical
company developing nucleic acid skin delivery technologies
and therapeutics for skin disorders, announced today that they will
collaborate on studying the potential utility of RXi’s proprietary
compounds in dermatology models. Under the collaboration, the
parties will explore the use of both existing and proprietary
delivery approaches for dermatological applications. Each party will
contribute technology and resources to the collaboration to evaluate
and develop novel transdermal RNAi delivery. Financial terms of the
collaboration were not disclosed.
"We have made excellent progress in the delivery of our novel rxRNA™
compounds in a variety of systemic and local applications, including
intradermal delivery,” said Noah D. Beerman, President and
Chief Executive
Officer of RXi. “As we refine the therapeutic focus for our
unique technology, in addition to the development of our own
proprietary technologies, including our ‘self delivering’ sd-rxRNA
compounds, we will continue to collaborate on complementary delivery
systems, to ensure the rapid progression of our compounds into
clinical development.”
RXi also recently announced new preclinical data exemplifying the
performance of the Company's proprietary sd-rxRNA™ compounds in an
in vivo model of compromised skin. Data generated using a
fluorescently-tagged sd-rxRNA compound demonstrate spontaneous
cellular uptake into dermal cells and a significant, sustained and
reproducible silencing of the targeted mRNA. The data presented
establish the efficacy of locally administered sd-rxRNA in
animal models and support the potential use of these novel
compounds for clinical applications where direct or local
administration is possible.
TransDerm was recently awarded a
NIH Grand Opportunities (GO) grant to compare existing skin
delivery technologies with the aim of using the most
promising
technologies in the clinic. “We are excited to work with RXi
to explore using their self-delivery technology for development of
therapeutics to treat skin disorders including pachyonychia
congenita,” said Roger L. Kaspar, Ph.D, Founder and CEO of TransDerm.
“The RXi technology has significant delivery advantages over the
siRNA used in our initial Phase 1b clinical trial and we are keen to
return to the clinic as soon as possible.”
About
RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company
pursuing the development and commercialization of proprietary
therapeutics based on RNA interference (RNAi) for the treatment of
human diseases. RXi has a comprehensive therapeutic platform that
includes both novel RNAi compounds and advanced delivery methods
that can be applied for local and systemic applications, against
targets that may be undruggable by other modalities. RXi uses its
proprietary version of RNAi compounds -- rxRNA™ -- that provide an
advanced alternative to conventional small interfering RNAs (siRNAs)
and define the next generation of RNAi technology. These include
rxRNAori™, rxRNAsolo™, and sd-rxRNA™ (or “self delivering” RNA),
which are distinct from, and potentially convey significant
advantages over classic siRNA’s. RXi Pharmaceuticals believes it is
well positioned to compete successfully in the RNAi-based
therapeutics market with its accomplished scientific advisors,
including Dr. Craig
Mello, recipient of the 2006 Nobel Prize for his co-discovery
of RNAi; a management team that is experienced in developing RNAi
products; and a strong and early, but broad,
intellectual property
position in RNAi chemistry and delivery.
www.rxipharma.com
About TransDerm, Inc.
TransDerm is dedicated to developing therapeutics for skin
disorders. In partnership with the International Pachyonychia
Congenita Consortium
(IPCC) and the PC Project (www.pachyonychia.org),
TransDerm is investigating different avenues for helping patients
suffering from the very rare skin disorder, pachyonychia congenita
(PC). TransDerm identified TD101, the first siRNA used in the clinic
to treat a skin disorder (PC) and the first to target a
genetic mutation.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements include, but are not limited to, statements about
future expectations, plan and future development of RXi
Pharmaceutical Corporation's products and technologies. These
forward-looking statements about future expectations, plans and
prospects of the development of RXi Pharmaceutical Corporation's
products and technologies involve significant risks, uncertainties
and assumptions, including the risk that the development of our RNAi-based
therapeutics may be delayed or may not proceed as planned and we may
not be able to complete development of any RNAi-based product, the
risk that the FDA approval process may be delayed for any drugs that
we develop, risks related to development and commercialization of
products by our competitors, risks related to our ability to control
the timing and terms of collaborations with third parties and the
possibility that other companies or organizations may assert patent
rights that prevent us from developing our products. Actual results
may differ materially from those contemplated by these
forward-looking statements.
RXi Pharmaceuticals
Corporation does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
CONTACT:
RXi Pharmaceuticals
Investor Relations
508-929-3615
ir@rxipharma.com
or
Investors
S. A. Noonan Communications
Susan Noonan
212-966-3650
susan@sanoonan.com
or
Media
Rx Communications Group
Eric Goldman
917-322-2563
egoldman@rxir.com
or
TransDerm, Inc.
Roger Kaspar, PhD
831 420-1684
Roger.Kaspar@TransDermInc.com